The tweet was deleted by the author.
But we saved everything 🙂.
Neumora Therapeutics announced today the appointment of Joshua Pinto, Ph.D., as the new chief executive officer and member of the Board of Directors.
The leadership change coincided with the company’s release of its second quarter 2026 financial results. Paul L. Berns, the outgoing CEO, will transition to the role of Executive Chair. The company did not provide additional details regarding its financial performance within the announcement. Further information is available on the Neumora Therapeutics website.
View post on X Loading...